CGRP monoclonal antibodies show insufficient benefit for cluster headache prevention in meta-analysis
Background
Cluster headache (CH) is characterized by severe, unilateral trigeminal autonomic cephalalgia, representing one of the most excruciating pain conditions. Current pharmacological treatment options for CH prevention are limited and often associated with significant side effects or inadequate efficacy. In contrast, calcitonin gene-related peptide (CGRP) monoclonal antibodies have revolutionized migraine prevention by targeting the CGRP pathway, a key mediator in nociceptive transmission. However, their specific efficacy and safety profile in the context of CH, a distinct primary headache disorder, remains largely uncertain, necessitating a comprehensive evaluation.
Study Design
Researchers conducted a systematic review and frequentist-Bayesian meta-analysis to evaluate the efficacy and safety of CGRP monoclonal antibodies for cluster headache. They systematically searched PubMed, Embase, Cochrane, Web of Science, and ClinicalTrials.gov through February 28, 2026. The analysis included four trials, encompassing a total of 655 participants. The primary outcome measured was the weekly cluster headache attack frequency, quantified as mean difference (MD) with 95% confidence intervals, comparing CGRP monoclonal antibodies against placebo. Sensitivity analyses included Bayesian meta-analysis with five prior specifications and trial sequential analysis.
Results
The pooled mean difference (MD) for weekly cluster headache attack frequency with CGRP monoclonal antibodies was -0.81 attacks per week (95%CI -2.24 to 0.62; P=0.265; I2=8%), indicating no statistically significant reduction. Neither the episodic (MD -1.21; 95%CI -5.20 to 2.78) nor chronic (MD -0.93; 95%CI -2.89 to 1.03) cluster headache subgroups reached statistical significance (P=0.90). The odds ratio (OR) for achieving a 50% or greater responder rate was 1.39 (95%CI 0.88-2.19; P=0.159), also not significant. However, the risk ratio (RR) for the 50% responder rate did reach significance at 1.25 (95%CI 1.04-1.49; P=0.017), a discrepancy attributed to high placebo response rates ranging from 27-53% across trials. Bayesian analysis revealed an 81.1% posterior probability of any benefit, but only a 17.9% probability that the true reduction would reach 2 or more attacks per week.
Trial sequential analysis indicated that for an assumed effect of 2.5 attacks per week, the accrued information exceeded the required information size (135.6%) without the cumulative Z-statistic crossing the efficacy boundary, suggesting insufficient evidence for this effect size.
Key Findings
- CGRP monoclonal antibodies did not significantly reduce weekly cluster headache attack frequency (MD -0.81/week, p=0.265).
- Neither episodic nor chronic cluster headache subgroups showed significant benefit.
- The odds ratio for a 50% responder rate was not significant (1.39, p=0.159).
- Risk ratio for 50% responder rate was significant (1.25, p=0.017), but driven by high placebo response (27-53%).
- Bayesian analysis showed only 17.9% probability of reducing attacks by 2 or more per week.
Why It Matters
CGRP monoclonal antibodies are not yet a proven effective treatment for cluster headache prevention, despite their established success in migraine. This meta-analysis suggests that clinicians and patients should manage expectations regarding the efficacy of this class of drugs for CH. While a modest benefit cannot be entirely ruled out, the current evidence does not support clinically meaningful efficacy. For biohackers or individuals exploring off-label use, this indicates that current protocols for CH should not rely on CGRP mAbs as a primary preventative strategy. Further research is crucial to identify specific CH subgroups or novel dosing regimens that might yield more robust and clinically significant benefits, potentially through different CGRP pathway modulation or combination therapies.
cgrp-monoclonal-antibodies
cluster-headache
meta-analysis
pain
neurology
cgrp-antagonist